Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.

2 Nov 2009

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems.

2 Nov 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

Shire announces Phase IIIb study results of Daytrana

Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

31 Oct 2009

Conference to address the need for gender specific diagnostic strategies for women

The 'Red Alert for Women's Hearts' conference, taking place on 5 November 2009, at the European Heart House, Sophia Antipolis, France, will address the subject of Women and CVD. The conference is jointly organised by the European Society of Cardiology (ESC) and European Heart Network (EHN), as part of Work Package 6 of the EuroHeart project .

31 Oct 2009

WakeMed Health & Hospitals and SCA team up to explore partnership opportunities

WakeMed Health & Hospitals and Surgical Care Affiliates (SCA) have entered into a Letter of Understanding (LOU) under which the two organizations will explore partnership opportunities.

31 Oct 2009

Study: Gene therapy can reduce symptoms of Huntington's disease

Researchers at the California Institute of Technology (Caltech) have shown that a highly specific intrabody (an antibody fragment that works against a target inside a cell) is capable of stalling the development of Huntington's disease in a variety of mouse models.

31 Oct 2009

Geron plans to advance clinical program for spinal cord injury

Geron Corporation today announced the company’s plan to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury.

31 Oct 2009

New teleneurology medicine program to provide 24-hour emergency services launched

Rural and small, suburban hospitals in North Carolina and Virginia can now provide a higher level of emergency stroke and critical neurology care, 24 hours a day, 365 days a year, as part of a new teleneurology medicine program announced Oct. 26, 2009, by Forsyth Medical Center (FMC).

31 Oct 2009

Individualized MicroNutrient Testing for patients

In response to the current trend toward personalized medicine, the Beaumont Weight Control Center, affiliated with Beaumont Hospitals, a major Detroit-area health system, now offers individualized MicroNutrient Testing for patients.

31 Oct 2009

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.

30 Oct 2009

MSC's Quality Initiative Programs to support best practice-based training for healthcare professionals

MSC's Sepsis Program has demonstrated the capability to increase tested knowledge in early identification and treatment of sepsis among trainees by over 46 percent. The program has been delivered to healthcare providers representing a range of institutions, from community hospitals to large academic teaching hospitals, demonstrating wide applicability among healthcare professionals with varied clinical backgrounds and previous training.

30 Oct 2009

Isotechnika Pharma develops portfolio of NICAMs with potent cyclophilin inhibition

Isotechnika Pharma Inc. today announced that it has developed a portfolio of non-immunosuppressive cyclosporine analogue molecules (NICAMs) with potent cyclophilin inhibition. Cyclophilin inhibition has garnered considerable attention as a novel therapy in the treatment of a wide range of diseases including hepatitis C, stroke, and chronic neurological disorders such as Parkinson's, Lou Gehrig's, and Alzheimer's.

30 Oct 2009

Case Western Reserve awarded $14.7M to lead study on effects of lowering systolic blood pressure

Case Western Reserve University School of Medicine has received a $14.7 million, nine-year contract from the National Institutes of Health to be one of five institutions to lead a trial to determine if lowering systolic blood pressure in hypertensive patients, without diabetes, to below the currently recommended level can reduce the incidence of cardiovascular and kidney disease and slow cognitive decline.

30 Oct 2009

Thrombolytic therapy can reduce stroke disability if given within the first few hours

Routing stroke patients directly to designated stroke centres - instead of taking them to the nearest hospital - dramatically increased access to a key clot-busting drug that can reduce stroke disability if given within the first few hours of symptoms, researchers report in Stroke: Journal of the American Heart Association.

30 Oct 2009

NIH launches randomized trail to determine whether lower BP goal cuts the risk of heart and kidney diseases

The National Institutes of Health is launching a large multicenter randomized clinical trial to determine whether maintaining blood pressure levels lower than current recommendations further reduces the risk of cardiovascular and kidney diseases, or age-related cognitive decline.

30 Oct 2009

Bolton Medical reports first U.S. trial of its Relay Plus System for endovascular stent-graft procedures

Bolton Medical announced today the first use of its new Relay Plus System in the U.S. Relay Clinical Trial. The case took place at the University of Pennsylvania Medical Center in Philadelphia, PA.

29 Oct 2009

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

The management of dyslipidemia continues to evolve and despite improvements in recurrent cardiovascular events and a decrease in cardiac mortality, cardiovascular disease (CVD) still represents the major burden of disease in this country.

29 Oct 2009

NMT Medical reports financial results for third-quarter 2009; narrows net loss to $0.22 per share

NMT Medical, Inc., an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures, today announced financial results for the quarter and nine months ended September 30, 2009.

29 Oct 2009

Simcere Pharmaceutical Group to control a 50.77% stake in Jiangsu Yanshen

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire a 74.49% stake in ChinaVax, a Cayman Islands company that, as its sole business, holds a 13.27% stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen").

29 Oct 2009

Stroke News and Research

Further Reading

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

Amgen publishes Phase 3 study results of Aranesp

Shire announces Phase IIIb study results of Daytrana

Conference to address the need for gender specific diagnostic strategies for women

WakeMed Health & Hospitals and SCA team up to explore partnership opportunities

Study: Gene therapy can reduce symptoms of Huntington's disease

Geron plans to advance clinical program for spinal cord injury

New teleneurology medicine program to provide 24-hour emergency services launched

Individualized MicroNutrient Testing for patients

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

MSC's Quality Initiative Programs to support best practice-based training for healthcare professionals

Isotechnika Pharma develops portfolio of NICAMs with potent cyclophilin inhibition

Case Western Reserve awarded $14.7M to lead study on effects of lowering systolic blood pressure

Thrombolytic therapy can reduce stroke disability if given within the first few hours

NIH launches randomized trail to determine whether lower BP goal cuts the risk of heart and kidney diseases

Bolton Medical reports first U.S. trial of its Relay Plus System for endovascular stent-graft procedures

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

NMT Medical reports financial results for third-quarter 2009; narrows net loss to $0.22 per share

Simcere Pharmaceutical Group to control a 50.77% stake in Jiangsu Yanshen

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News